UBS Group’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $84.3K | Buy |
104,204
+8,048
| +8% | +$6.51K | ﹤0.01% | 6105 |
|
|
2025
Q1 | $73.8K | Buy |
96,156
+28,766
| +43% | +$22.1K | ﹤0.01% | 6011 |
|
|
2024
Q4 | $85.9K | Buy |
67,390
+60,374
| +861% | +$77K | ﹤0.01% | 5752 |
|
|
2024
Q3 | $14.5K | Sell |
7,016
-3,918
| -36% | -$8.11K | ﹤0.01% | 6334 |
|
|
2024
Q2 | $41.7K | Sell |
10,934
-4,721
| -30% | -$18K | ﹤0.01% | 5686 |
|
|
2024
Q1 | $74.2K | Sell |
15,655
-4,218
| -21% | -$20K | ﹤0.01% | 5186 |
|
|
2023
Q4 | $84.9K | Buy |
19,873
+12,465
| +168% | +$53.2K | ﹤0.01% | 5079 |
|
|
2023
Q3 | $22.9K | Buy |
7,408
+516
| +7% | +$1.59K | ﹤0.01% | 5603 |
|
|
2023
Q2 | $31K | Buy |
6,892
+5,912
| +603% | +$26.6K | ﹤0.01% | 5631 |
|
|
2023
Q1 | $5.59K | Sell |
980
-57
| -5% | -$325 | ﹤0.01% | 6921 |
|
|
2022
Q4 | $6.26K | Buy |
1,037
+969
| +1,425% | +$5.85K | ﹤0.01% | 7864 |
|
|
2022
Q3 | $0 | Sell |
68
-2,638
| -97% | – | ﹤0.01% | 9580 |
|
|
2022
Q2 | $14K | Buy |
2,706
+2,523
| +1,379% | +$13.1K | ﹤0.01% | 6378 |
|
|
2022
Q1 | $1K | Sell |
183
-1,755
| -91% | -$9.59K | ﹤0.01% | 8843 |
|
|
2021
Q4 | $23K | Sell |
1,938
-35,063
| -95% | -$416K | ﹤0.01% | 6567 |
|
|
2021
Q3 | $1.16M | Buy |
37,001
+29,433
| +389% | +$920K | ﹤0.01% | 3145 |
|
|
2021
Q2 | $216K | Sell |
7,568
-14,768
| -66% | -$421K | ﹤0.01% | 4270 |
|
|
2021
Q1 | $968K | Buy |
22,336
+19,755
| +765% | +$856K | ﹤0.01% | 3389 |
|
|
2020
Q4 | $185K | Buy |
2,581
+1,158
| +81% | +$83K | ﹤0.01% | 4317 |
|
|
2020
Q3 | $43K | Buy |
+1,423
| New | +$43K | ﹤0.01% | 4902 |
|